Biopsafe provides an innovative container for safer handling in biopsy procedures. The company’s revenue amount to approximately 50 MDKK with good profitability and sales on several European markets.
Biopsafe will be part of MedCap’s business area MedTech.
”Biopsafe has an innovative product and has established a leading position in its niche on several European markets. The company makes a nice addition to the business area Medtech and we look forward to continuing the development together with the team.”, comments Anders Dahlberg, CEO MedCap.
The acquisition is made at a cash purchase price of 115 MDKK adjusted for cash and net debt at closing which occurred on June 26th.